21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology
Link
http://www.nature.com/articles/s41523-018-0090-6.pdf
Reference16 articles.
1. Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726–3734 (2006).
2. Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl. Cancer Inst. 101, 1446–1452 (2009).
3. Sparano, J. A. & Paik, S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26, 721–728 (2008).
4. Albain, K. S. et al. Prognostic and 286 predictive value of the 21-gene recurrence score assay in postmenopausal women with node-287 positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis 288 of a randomised trial. Lancet Oncol. 11, 55–65 (2010).
5. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).
Cited by 63 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors;BMC Cancer;2023-10-24
2. Recent Advances and Applications of Ambient Mass Spectrometry Imaging in Cancer Research: An Overview;Mass Spectrometry;2023-09-28
3. An apparent quandary: adoption of polygenics and gene panels for personalised breast cancer risk stratification;BJC Reports;2023-09-18
4. The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective;Journal of Medical Economics;2023-08-07
5. Invasive breast carcinoma of no special type with medullary pattern: A case report at a tertiary facility in Tanzania;Clinical Case Reports;2023-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3